China’s Betta Pharmaceuticals (SHE: 300558) has announced the enrollment of the first patient in a Phase I/II clinical study for its first-in-class bispecific antibody (BsAb), BPB-101. The molecule is currently being assessed for the treatment of advanced malignant solid tumors.
BPB-101: A Trifunctional IgG1 Subtype Humanized Antibody
BPB-101 is a trifunctional IgG1 subtype humanized antibody that specifically targets and binds to the GARP-TGF-β complex, mature TGF-β, and PD-L1. This innovative drug candidate is under development to treat a range of cancers, including non-small cell lung cancer, ovarian, breast, and esophageal cancers, melanoma, endometrial cancer, bladder cancer, bile duct cancer, colorectal cancer, liver cancer, and others.
Preclinical Studies and Potential Impact on Tumor Growth
Preclinical studies have demonstrated that BPB-101 can restore and enhance the killing effect of immune cells against tumor cells, thereby inhibiting tumor growth and survival. The ability of BPB-101 to target multiple pathways simultaneously positions it as a promising candidate in the field of immuno-oncology, with the potential to offer new treatment options for patients with advanced solid tumors.-Fineline Info & Tech
